Strike two for Novartis’ lung cancer antibody canakinumabExpectations for Novartis’ canakinumab as a therapy for cancer have taken another dive, after a second phase 3 Share XStrike two for Novartis’ lung cancer antibody canakinumabhttps://pharmaphorum.com/news/strike-two-for-novartis-lung-cancer-antibody-canakinumab/
Novartis’ canakinumab falls short in phase 3 lung cancer trialNovartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless Share XNovartis’ canakinumab falls short in phase 3 lung cancer trialhttps://pharmaphorum.com/news/novartis-canakinumab-falls-short-in-phase-3-lung-cancer-trial/
